Dianthus Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 13.75 million compared to USD 7.09 million a year ago. Basic loss per share from continuing operations was USD 0.54 compared to USD 8.1 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | -3.56% |
|
+29.16% | +150.00% |
12/06 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
12/06 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+150.00% | 763M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024